Quantitative assessment of cross-sectional muscle area, functional status, and muscle strength in men with the acquired immunodeficiency syndrome wasting syndrome

被引:54
作者
Grinspoon, S
Corcoran, C
Rosenthal, D
Stanley, T
Parlman, K
Costello, M
Treat, M
Davis, S
Burrows, B
Basgoz, N
Klibanski, A
机构
[1] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Dept Phys Therapy, Boston, MA 02114 USA
[5] Harvard Univ, Sch Med, Boston, MA 02114 USA
[6] Boston Vet Affairs, Med Ctr, Dept Radiol, Boston, MA 02130 USA
[7] Boston Univ, Sch Med, Boston, MA 02130 USA
关键词
D O I
10.1210/jc.84.1.201
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The acquired immunodeficiency syndrome wasting syndrome (AWS) in men is characterized by the loss of lean body mass out of proportion to weight. Although the wasting syndrome has been thought to contribute to reduced functional capacity, the relationships among lean body mass, muscle size, functional status, and regional muscle strength have not previously been investigated in this population. In this study, 24 eugonadal men with the AWS (weight <90% of the ideal body weight or weight loss >10% from preillness maximum) underwent determination of body composition by dual energy x-ray absorptiometry (DXA), K-40 isotope analysis, urinary creatinine excretion, and quantitative computed tomographic analysis of cross-sectional muscle areas of the midarm and thigh. Overall exercise functional capacity was evaluated using the 6-min walk test, and performance of upper and lower extremities was determined with the quantitative muscle function test. Subjects were 37 +/- 1 yr of age and weighed 95.5 +/- 3.0% of ideal body weight, with a body mass index of 21.9 +/- 0.7 kg/m(2) and an average weight loss of 15 +/- 1%. The mean CD4 count among the subjects was 354 +/- 70 cells/mm(3), and viral load was 58,561 +/- 32,205 copies. Sixty-two percent of subjects were receiving protease inhibitor therapy. The subjects demonstrated 90% of the expected muscle mass by the creatinine height index method. Overall performance status on the Karnofsky scale was highly correlated to weight (r = 0.51; P = 0.018; by body mass index), lean body mass (r = 0.46; P = 0.036; by DXA), and body cell mass (r = 0.47; P = 0.037; by K-40 isotope analysis). Cross-sectional muscle area of the upper extremity was the best predictor (P < 0.001) of Karnofsky score, accounting for 52% of the variability in a stepwise regression analysis. Upper body muscle strength was most significantly predicted by lean body mass (by DXA; r(2) = 0.78; P < 0.0001), whereas lower body strength and performance on the 6-min walk test were best predicted by lower extremity cross-sectional muscle area (r(2) = 0.70; P < 0.0001 and r(2) = 0.26; P = 0.030, respectively). These data demonstrate that cross-sectional muscle area is highly predictive of functional status and muscle strength in men with the AWS.
引用
收藏
页码:201 / 206
页数:6
相关论文
共 28 条
[1]   A COMPARATIVE TRIAL OF DIDANOSINE OR ZALCITABINE AFTER TREATMENT WITH ZIDOVUDINE IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
ABRAMS, DI ;
GOLDMAN, AI ;
LAUNER, C ;
KORVICK, JA ;
NEATON, JD ;
CRANE, LR ;
GRODESKY, M ;
WAKEFIELD, S ;
MUTH, K ;
KORNEGAY, S ;
COHN, DL ;
HARRIS, A ;
LUSKINHAWK, R ;
MARKOWITZ, N ;
SAMPSON, JH ;
THOMPSON, M ;
DEYTON, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (10) :657-662
[2]   QUANTITATIVE MOTOR-ASSESSMENT IN AMYOTROPHIC-LATERAL-SCLEROSIS [J].
ANDRES, PL ;
HEDLUND, W ;
FINISON, L ;
CONLON, T ;
FELMUS, M ;
MUNSAT, TL .
NEUROLOGY, 1986, 36 (07) :937-941
[3]  
[Anonymous], MMWR
[4]  
BULCKE JA, 1979, NEURORADIOLOGY, V17, P127
[5]  
Finison LJ, 1996, ARCH PHYS MED REHAB, V77, P1251
[6]   TOTAL SODIUM, POTASSIUM AND CHLORIDE IN ADULT MAN [J].
FORBES, GB ;
LEWIS, AM .
JOURNAL OF CLINICAL INVESTIGATION, 1956, 35 (06) :596-600
[7]   Loss of lean body and muscle mass correlates with androgen levels hypogonadal men with acquired immunodeficiency syndrome and wasting [J].
Grinspoon, S ;
Corcoran, C ;
Lee, K ;
Burrows, B ;
Hubbard, J ;
Katznelson, L ;
Walsh, M ;
Guccione, A ;
Cannan, J ;
Heller, H ;
Basgoz, N ;
Klibanski, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (11) :4051-4058
[8]   Effects of androgen administration in men with the AIDS wasting syndrome - A randomized, double-blind, placebo-controlled trial [J].
Grinspoon, S ;
Corcoran, C ;
Askari, H ;
Schoenfeld, D ;
Wolf, L ;
Burrows, B ;
Walsh, M ;
Hayden, D ;
Parlman, K ;
Anderson, E ;
Basgoz, N ;
Klibanski, A .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (01) :18-+
[9]   HOW SHOULD WE MEASURE FUNCTION IN PATIENTS WITH CHRONIC HEART AND LUNG-DISEASE [J].
GUYATT, GH ;
THOMPSON, PJ ;
BERMAN, LB ;
SULLIVAN, MJ ;
TOWNSEND, M ;
JONES, NL ;
PUGSLEY, SO .
JOURNAL OF CHRONIC DISEASES, 1985, 38 (06) :517-524
[10]   MEASUREMENT OF MUSCLE MASS IN HUMANS - VALIDITY OF THE 24-HOUR URINARY CREATININE METHOD [J].
HEYMSFIELD, SB ;
ARTEAGA, C ;
MCMANUS, C ;
SMITH, J ;
MOFFITT, S .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1983, 37 (03) :478-494